NIH ACTIV Vaccine Working Group Weighs Role of Human Challenge Studies for Sars-CoV-2 Vaccine Development
July 02, 2020
July 02, 2020
WASHINGTON, July 2 -- The U.S. Department of Health and Human Services' National Institutes of Health issued the following news release:
In a Perspective for the New England Journal of Medicine(link is external), members of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for . . .
In a Perspective for the New England Journal of Medicine(link is external), members of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working Group assess practical considerations and prerequisites for using controlled human infection models (CHIMs), which can be used for . . .